Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study

NCT01600742 Phase 2 TERMINATED

Vorinostat is a potent and well tolerated HDAC inhibitor. It has been reported to enhance radiosensitivity of cancer cells. We hypothesize that the addition of vorinostat to WBRT may increase therapeutic efficacy for patients with brain metastases.

Details

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	TERMINATED
Enrolment	4
Start date	2012-08
Completion	2013-12

Conditions

• Brain Metastasis

Interventions

• Vorinostat
• Placebo

Primary outcomes

• To evaluate brain-specific progression free survival rate at 6 months — 6 months

Countries

Taiwan